Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021 – Beyond the Abstract
Treatment options for metastatic urothelial carcinoma, cisplatin-based chemotherapy, combination enfortumab vedotin–pembrolizumab, Nivolumab as adjuvant treatment in high-risk muscle-invasive UC.